Interstitial Lung Diseases of Unknown Cause: Disorders Characterized by Chronic Inflammation of the Lower Respiratory Tract

New England Journal of Medicine

Volumn 310, Issue 4, 1984, Pages 235-244

  Crystal, Ronald G ^a   Bitterman, Peter B ^a   Rennard, Stephen I ^a   Hance, Allan J ^a   Keogh, Brendan A ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GALLIUM 67; RADIOISOTOPE;

BONE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; DIAGNOSIS; DRUG THERAPY; EOSINOPHILIC GRANULOMA; ETIOLOGY; FIBROSING ALVEOLITIS; HISTIOCYTOSIS; HISTOPATHOLOGY; HUMAN; INTERSTITIAL LUNG DISEASE; LOWER RESPIRATORY TRACT; LUNG LAVAGE; RESPIRATORY SYSTEM; SARCOIDOSIS; THERAPY; TRANSBRONCHIAL BIOPSY;

ANTIGEN-ANTIBODY COMPLEX; BIOPSY; COMPLEMENT SYSTEM PROTEINS; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; KILLER CELLS; LYMPHOCYTES; MACROPHAGES; PULMONARY ALVEOLI; PULMONARY FIBROSIS; SARCOIDOSIS; SMOKING; T-LYMPHOCYTES;

EID: 0021365617     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198401263100406     Document Type: Review

References (69)

1. Robbins RA, Gadek JE, Chen YF, Rennard SI, Crystal RG. Modulation of alveolar macrophage function by the alternative pathway: properdin factor Bb stimulation of neutrophil chemotactic factor release. Clin Res 1982; 30: 356A. abstract.
2. Mitchell DN, Scadding JG. Sarcoidosis. Am Rev Respir Dis 1974; 110: 774–802.
3. Israel HL. Prognosis of sarcoidosis. Ann Intern Med 1970; 73: 1038–9.
4. Bacharach T. Sarcoidosis: a clinical review of 111 cases. Am Rev Respir Dis 1961; 84: 12–6.
5. Siltzbach LE, ed. Seventh International Conference on Sarcoidosis and Other Granulomatous Diseases. Ann NY Acad Sci 1976; 278: 1–751.
6. Levinský L, Cummiskey J, Rømer FK, et al. Sarcoidosis in Europe: a cooperative study. Ann NY Acad Sci 1976; 278: 335–46.
7. Sartwell PE. Racial differences in sarcoidosis. Ann NY Acad Sci 1976; 278: 368–70.
8. Chretien J, Marsac J, Saltiel JC, eds. Ninth International Conference on Sarcoidosis and Other Granulomatous Disorders. Paris: Pergamon Press, 1982.
9. Siltzbach LE. Sarcoidosis. In: Fishman AP, ed. Pulmonary diseases and disorders. New York: McGraw-Hill 1980:889–908.
10. Leiberman J, Nosal A, Schlessner LA, Sastre-Foken A. Serum angiotensin-converting enzyme for diagnosis and therapeutic evaluation of sarcoidosis. Am Rev Respir Dis 1979; 120: 329–35.
11. DeRemee RA, Rohrbach MS. Serum angiotensin-converting enzyme activity in evaluating the clinical course of sarcoidosis. Ann Intern Med 1980; 92: 361–5.
12. Rohrbach MS, DeRemee RA. Pulmonary sarcoidosis and serum angiotensin-converting enzyme. Mayo Clin Proc 1982; 57: 64–6.
13. Hunninghake GW, Fulmer JD, Young RC Jr, Crystal RG. Comparison of lung and peripheral blood lymphocyte subpopulations in pulmonary sarcoidosis. In: Williams WJ, Davies BH, eds. Eighth International Conference on Sarcoidosis and Other Granulomatous Diseases. Cardiff: Alpha Omega, 1980:426–35.
14. Westcott JL, Noehren TH. Bronchial stenosis in chronic sarcoidosis. Chest 1973; 63: 893–7.
15. Dines DE, Stubbs SE, McDougall JC. Obstructive disease of the airways associated with stage I sarcoidosis. Mayo Clin Proc 1978; 53: 788–91.
16. Soler P, Basset F, Bernaudin JF, Chretien J. Morphology and distribution of the cells of a sarcoid granuloma: ultrastructural study of serial sections. Ann NY Acad Sci 1976; 278: 147–60.
17. Line BR, Hunninghake GW, Keogh BA, Jones AE, Johnston GS, Crystal RG. Gallium-67 scanning to stage the alveolitis of sarcoidosis: correlation with clinical studies, pulmonary function studies, and bronchoalveolar lavage. Am Rev Respir Dis 1981; 123: 440–6.
18. Line BR, Hunninghake GW, Keogh BA, Crystal RG. Gallium-67 scanning asan indicator of the activity of sarcoidosis. In: Fanburg BL, ed. Sarcoidosis and other granulomatous diseases of the lung. New York: Marcel Dekker 1983:287–322.
19. Wallaert B, Ramon P, Fournier E, Tonnel AB, Voisin C. Bronchoalveolar lavage, serum angiotensin-converting enzyme and gallium-67 scanning in extrathoracic sarcoidosis. Chest 1982; 82: 553–5.
20. Schoenberger CI, Line BR, Keogh BA, Hunninghake GW, Crystal RG. Lung inflammation in sarcoidosis: comparison of serum angiotensin-converting enzyme levels with bronchoalveolar lavage and gallium-67 scanning assessment of the T lymphocyte alveolitis. Thorax 1982; 37: 19–25.
21. Boros DL. Granulomatous inflammations. Prog Allergy 1978; 24: 183–267.
22. Hunninghake GW, Keogh BA, Line BR, et al. Pulmonary sarcoidosis: pathogenesis and therapy. In: Boros D, Yoshida T, eds. Basic and clinical aspects of granulomatous diseases. New York: Elsevier/North-Holland, 1980:275–90.
23. Spector WG. Epithelioid cells, giant cells, and sarcoidosis. Ann NY Acad Sci 1976; 278: 3–6.
24. Rosen Y, Athanassiades TJ, Moon S, Lyons HA. Nongranulomatous interstitial pneumonitis in sarcoidosis: relationship to the development of epithelioid granulomas. Chest 1978; 74: 122–5.
25. Familial associations in sarcoidosis: a report to the Research Committee of the British Thoracic and Tuberculosis Association. Tubercle 1973; 54: 87–98.
26. Brewerton DA, Cockburn C, James DCO, James DG, Neville E. HLA antigens in sarcoidosis. Clin Exp Immunol 1977; 27: 227–9.
27. Sharma OP, Neville E, Walker AN, James DG. Familial sarcoidosis: a possible genetic influence. Ann NY Acad Sci 1976; 278: 386–400.
28. Huang CT, Heurich AE, Rosen Y, Moon S, Lyons HA. Pulmonary sarcoidosis: roentgenographic, functional, and pathologic correlations. Respiration 1978; 37: 337–45.
29. Rosen Y, Vuletin JC, Pertschuk LP, Silverstein E. Sarcoidosis from the pathologist's viewpoint. Pathol Annu 1979; 14: Part 1: 405–39.
30. Keogh B, Hunninghake G, Line B, Price D, Young R, Crystal R. Alveolitis parameters as predicators of the natural history of pulmonary sarcoidosis. Clin Res 1981; 29: 447A. abstract.
31. Keogh BA, Hunninghake GW, Line BR, Crystal RG. The alveolitis bf pulmonary sarcoidosis: evaluation of natural history and alveolitis dependent changes in lung function. Am Rev Respir Dis 1983; 128: 256–65.
32. Pacheco Y, Cordier G, Perrin-Fayolle M, Revillard J-P. Flow cytometry analysis of T lymphocytes in sarcoidosis. Am J Med 1982; 73: 82–8.
33. Pinkston P, Bitterman PB, Crystal RG. Spontaneous release of interleukin-2 by lung T lymphocytes in active pulmonary sarcoidosis. N Engl J Med 1983; 308: 793–800.
34. Hunninghake GW, Bedell GN, Zavala DC, Monnick M, Brady M. Role of interleukin-2 release by lung T cell in active pulmonary sarcoidosis. Am Rev Respir Dis 1983; 128: 634–8.
35. Watson J, Frank B, Mochizuki D, Gillis S. The biochemistry and biology of interleukin-2. In: Mizel SB, ed. Lymphokines. Vol. 6. New York: Academic Press, 1982:95–116.
36. Mier JW, Gallo RC. The purification and properties of human T cell growth factor. J Immunol 1982; 128: 1122–7.
37. Ward PA, Remold HG, David JR. Leukotactic factor produced by sensitized lymphocytes. Science 1969; 163: 1079–81.
38. Epstein WL. Granulomatous hypersensitivity. Prog Allergy 1967; 11: 36–88.
39. Byrne EB, Evans AS, Fouts DW, Israel HL. Serological hyperreactivity to Epstein–Barr virus and other viral antigens in sarcoidosis. In: Iwai K, Hosoda Y, eds. Proceedings of the 6th International Conference on Sarcoidosis. Baltimore: University Park Press, 1974:218–25.
40. Valeyre D, Saumon G, Bladier D, et al. The relationships between noninvasive explorations in pulmonary sarcoidosis of recent origin, as shown in bronchoalveolar lavage, serum, and pulmonary function tests. Am Rev Respir Dis 1982; 126: 41–5.
41. Hunninghake GW. Release of interleukin-1 by alveolar macrophages of patients with active pulmonary sarcoidosis. Am Rev Respir Dis (in press).
42. Given JT, Fells G. Saltzman L, et al. Differences in spontaneous cytotoxic effector functions of alveolar macrophages in interstitial lung disease. Am Rev Respir Dis 1983; 127: Part 2: 280. abstract.
43. Oppenheim JJ. Lymphokines. In: Openheim JJ, Rosenstreich M, Potter M, eds. Cellular functions in immunity and inflammation. New York: Elsevier/North Holland, 1981:259–82.
44. David JR, Rocklin RE. Lymphocyte mediators: “the lymphokines.” In: Samter M, ed. Immunological diseases. Vol. 1. Boston: Little, Brown, 1978:307–24.
45. Gupta RC, Kueppers F, DeRemee RA, Huston KA, McDuffie FC. Pulmonary and extrapulmonary sarcoidosis in relation to circulating immune complexes: a quantitation of immune complexes by two radioimmunoassays. Am Rev Respir Dis 1977; 116: 261–6.
46. Auld D. Pathology of eosinophilic granuloma of the lung. Arch Pathol 1957; 63: 113–31.
47. Lichtenstein L. Histiocytosis X: integration of eosinophilic granuloma of bone, “Letterer–Siwe disease,” and “Schüller-Christian disease” as related manifestations of a single nosologic entity. Arch Pathol 1953; 56: 84–102.
48. Groopman JE, Golde DW. The histiocytic disorders: a pathophysiologic analysis. Ann Intern Med 1981; 94: 95–107.
49. Jaffe HL, Lichtenstein L. Eosinophilic granuloma of bone: a condition affecing one, several or many bones, but apparently limited to the skeleton, and representing the mildest clinical expression of the peculiar inflammatory histiocytosis also underlying Letterer–Siwe disease and Schüller–Christian disease. Arch Pathol 1944; 37: 99–118.
50. Parkinson T. Eosinophilic xanthomatous granuloma with honeycomb lungs. Br Med J 1949; 1: 1029–30.
51. Lewis JG. Eosinophilic granuloma and its variants with special reference to lung involvement: a report of 12 patients. Q J Med 1964; 33: 337–59.
52. Friedman PJ, Liebow AA, Sokoloff J. Eosinophilic granuloma of lung: clinical aspects of primary pulmonary histiocytosis in the adult. Medicine (Baltimore) 1981; 6: 385–96.
53. Lacronique J, Roth C, Battesti J-P, Basset F, Chretien J. Chest radiological features of pulmonary histiocytosis X: a report based on 50 adult cases. Thorax 1982; 37: 104–9.
54. Basset F, Nexelof C. L'histocytose X: microscopie électronique: culture “in vitro” et histo-enzymologie: discussion a propos de 21 cas. Rev Fr Etudes Clin Biol 1969; 14: 31–45.
55. Fithian E, Kung P, Goldstein G, Rubenfeld M, Fenoglio C, Edelson R. Reactivity of Langerhans cells with hybridoma antibody. Proc Natl Acad Sci USA 1981; 78: 2541–4.
56. Basset F, Soler P, Jaurand MC, Bignon J. Ultrastructural examination of broncho-alveolar lavage for diagnosis of pulmonary histiocytosis X: preliminary report on 4 cases. Thorax 1977; 32: 303–6.
57. Kawanami O, Basset F, Ferrans VJ, Soler P, Crystal RG. Pulmonary Langerhan's cells in patients with fibrotic lung disorders. Lab Invest 1981; 44: 227–33.
58. Chollet S, Dournovo P, Richard MS, Soler P, Basset F. Reactivity of histiocytosis X cells with monoclonal anti-T6 antibody. N Engl J Med 1982; 307: 685.
59. Shelley WB, Juhlin L. Langerhans cells form a reticuloepithelial trap for external contact antigens. Nature 1976; 261: 46–7.
60. Rennard S, Bitterman P, Davis WB, et al. Destruction and fibrosis of the lung parenchyma in adult pulmonary histiocytosis X is mediated by alveolar mononuclear phagocytes. Clin Res 1983; 31: 420A. abstract.
61. Katz SI, Tamaki K, Sachs DH. Epidermal Langerhans cells are derived from cells originating in bone marrow. Nature 1979; 282: 324–6.
62. Daniele RP, Henson PM, Fantone JC, Ward PA, Dreisen RB. Immune complex injury of the lung. Am Rev Respir Dis 1981; 124: 738–55.
63. Wall CP, Gaensler EA, Carrington CB, Hayes JA. Comparison of transbronchial and open biopsies in chronic infiltrative lung diseases. Am Rev Respir Dis 1981; 123: 280–5.
64. Bohlig HL, Bristol LJ, Cartier PH, et al. UICC/Cincinnati classification of the radiographic appearances of pneumoconiosis: a cooperative study by the UICC Committee. Chest 1970; 58: 57–67.
65. Auerbach O, Garfinkel L, Hammond EC. Relation of smoking and age to findings in lung parenchyma: a microscopic study. Chest 1974; 65: 29–35.
66. Hoidal JR, Fox RB, LeMarbe PA, Perri R, Repine JE. Altered oxidative metabolic responses in vitro of alveolar macrophages from asymptomatic cigarette smokers. Am Rev Respir Dis 1981; 123: 85–9.
67. Hunninghake G, Crystal R. Cigarette smoking and lung destruction: accumulation of neutrophil in the lungs of cigarette smokers. Am Rev Respir Dis 1983; 128: 833–8.
68. Riley DJ, Kerr JS, Berg RA, et al. Prevention of bleomycin induced pulmonary fibrosis in the hamster by cis-4-hydroxy-L-proline. Am Rev Respir Dis 1981; 123: 388–93.
69. Reiser KM, Last JA. Silicosis and fibrogenesis: fact and artifact. Toxicology 1979; 13: 51–72.